• Je něco špatně v tomto záznamu ?

Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study

I. Demel, D. Skopal, E. Šafránková, P. Rozsívalová, P. Jindra, J. Šrámek, A. Turková, J. Vydra, K. Labská, J. Vedrová, M. Čerňan, T. Szotkowski, H. Móciková, L. Hynková, O. Šušol, I. Kováčová, D. Belada, R. Hájek

. 2024 ; 103 (3) : 981-992. [pub] 20231214

Jazyk angličtina Země Německo

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006957

Grantová podpora
00669806 Ministerstvo Zdravotnictví Ceské Republiky
UHHK Ministerstvo Zdravotnictví Ceské Republiky
00179906 Ministerstvo Zdravotnictví Ceské Republiky
IGA_LF_2023_005 Univerzita Palackého v Olomouci
programme Cooperatio lékařská fakulta Univerzity Karlovy
research area ONCO lékařská fakulta Univerzity Karlovy
SVV 260 665 lékařská fakulta Univerzity Karlovy

Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld's efficacy against severe COVID-19 in patients with hematology malignancies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006957
003      
CZ-PrNML
005      
20240423155615.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-023-05572-0 $2 doi
035    __
$a (PubMed)38092996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Demel, Ivo $u Department of Haematooncology, University Hospital Ostrava, 17. Listopadu 1790/5, 708 52, Ostrava, Czech Republic. ivo.demel@fno.cz $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. ivo.demel@fno.cz $1 https://orcid.org/0000000205189581 $7 xx0268008
245    10
$a Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study / $c I. Demel, D. Skopal, E. Šafránková, P. Rozsívalová, P. Jindra, J. Šrámek, A. Turková, J. Vydra, K. Labská, J. Vedrová, M. Čerňan, T. Szotkowski, H. Móciková, L. Hynková, O. Šušol, I. Kováčová, D. Belada, R. Hájek
520    9_
$a Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld's efficacy against severe COVID-19 in patients with hematology malignancies.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a preexpoziční profylaxe $7 D065129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a monoklonální protilátky $7 D000911
650    12
$a hematologické nádory $x komplikace $x farmakoterapie $x epidemiologie $7 D019337
651    _2
$a Česká republika $7 D018153
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skopal, David $u 4th Department of Internal Medicine - Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Šafránková, Eliška $u 4th Department of Internal Medicine - Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Rozsívalová, Petra $u Hospital Pharmacy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Jindra, Pavel $u Department of Haematology & Oncology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Šrámek, Jiří $u Department of Haematology & Oncology, University Hospital Pilsen, Pilsen, Czech Republic $u Department of Histology and Embryology, Faculty of Medicine, Pilsen, Czech Republic
700    1_
$a Turková, Adéla $u Department of Haematology & Oncology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Vydra, Jan $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Labská, Klára $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Vedrová, Jana $u Institute of Haematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Čerňan, Martin $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Szotkowski, Tomáš $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Móciková, Heidi $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Hynková, Lenka $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Šušol, Ondrej $u Department of Haematooncology, University Hospital Ostrava, 17. Listopadu 1790/5, 708 52, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Kováčová, Ingrid $u Department of Haematooncology, University Hospital Ostrava, 17. Listopadu 1790/5, 708 52, Ostrava, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Haematology, Hospital and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Hájek, Roman $u Department of Haematooncology, University Hospital Ostrava, 17. Listopadu 1790/5, 708 52, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 103, č. 3 (2024), s. 981-992
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38092996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155611 $b ABA008
999    __
$a ok $b bmc $g 2081127 $s 1216724
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c 3 $d 981-992 $e 20231214 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a 00669806 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a UHHK $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 00179906 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a IGA_LF_2023_005 $p Univerzita Palackého v Olomouci
GRA    __
$a programme Cooperatio $p lékařská fakulta Univerzity Karlovy
GRA    __
$a research area ONCO $p lékařská fakulta Univerzity Karlovy
GRA    __
$a SVV 260 665 $p lékařská fakulta Univerzity Karlovy
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace